

Invented for life



BOSCH

Vivalytic STI

Multiplex PCR test for the detection of sexually transmitted infections at the Point of Care

√ivalytic from Bosch –
The universal diagnostic platform.
Universal, intuitive, fast.



√ivalytic

Vivalytic STI

Multiplex PCR test for the detection of sexually transmitted infections at the Point of Care

According to the World Health Organization (WHO), over 30 different bacterial species, viruses, and parasites have been identified as being involved in the spread of sexually transmitted infections (STIs). More than one million STIs are acquired worldwide every day, the majority of which are asymptomatic.¹ Currently, WHO estimates that there are about 374 million new infections with one of the four most common curable STIs chlamydia, gonorrhoea, syphilis, and trichomoniasis each year.¹

Within the European Region, the incidence of these curable STIs is among the lowest. Nevertheless, an increase in the incidence of STIs was observed in the EU between 2010 and 2019, with the number of reported cases of gonorrhoea more than doubling since 2010.²

A similar trend can also be seen for syphilis with numbers nine times higher in men than in women in the same period.³


Women are disproportionately affected by STIs and often experience complications including infertility and chronic

pelvic pain that can have lifelong impacts. STIs can lead to fatal consequences in pregnancy e.g., ectopic pregnancy, peripartum morbidity and mortality.⁴

The WHO's 2022–2030 global health sector strategies on STIs aim to end the health care issue of STIs by 2030. One of the recommended measures is to establish integrated testing as a key element of people-centered health services with multiplex testing and Point of Care testing playing a crucial role in the concept.⁵

Vivalytic STI - Point of Care for containment of STIs

- Immediate identification of 10 sexually transmitted pathogens within 2.5 hours at the Point of Care
- Only a few steps from sample to result
- No transport of specimens necessary
- No further laboratory equipment needed
- Clinicians can start treatment on the same day of testing



Sample material

Swab (urethral, vaginal, cervical),
urine

Volume

300 µl


Detection method

Microarray-based PCR test


Detectable pathogens

- *Chlamydia trachomatis*
- *Neisseria gonorrhoeae*
- *Trichomonas vaginalis*
- *Mycoplasma genitalium*
- *Treponema pallidum*
- *Mycoplasma hominis*
- *Ureaplasma urealyticum*
- *Haemophilus ducreyi*
- Herpes simplex virus I
- Herpes simplex virus II


Vivalytic workflow: Only a few steps from sample to result




① Scan sample code.



② Scan cartridge code.



③ Insert the sample and close cartridge lid.



④ Insert cartridge. The test starts automatically.

Our biocontent cooperation partner is:

RANDOX

Subject to technical modifications. Printed in Germany. Any color deviations are due to restrictions in the printing process. Printed on 100% chlorine-free bleached cellulose, produced in an environmentally friendly process. Not all products are available in all regions. Ask your local sales representative for availability in specific markets. For in vitro diagnostic use only.

Bosch Healthcare Solutions GmbH
Stuttgarter Str. 130, 71332 Waiblingen, Germany

¹ WHO, Sexually transmitted infections (STIs). [https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-\(stis\)](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)), Date of query 25.07.2023

² ECDC Surveillance Report Gonorrhoea; Annual Epidemiological Report for 2019

³ ECDC Surveillance Report Syphilis; Annual Epidemiological Report for 2019

⁴ Van Gerwen et al., Nat Microbiol. 2022 Aug;7(8):1116-1126

⁵ Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022